Literature DB >> 673314

Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031).

L Håkansson, I Könyves, L G Lindberg, T Möller.   

Abstract

The effect of Prednimustine was evaluated in 37 patients with generalised non-Hodgkin's lymphomas. The patients were divided into three groups according to dosage and previous treatment. Totally, in all three groups, 22 complete and 10 partial remissions were observed. During follow-up, five of the complete responders and all partial responders have relapsed. Leucopenia and thrombocytopenia were induced in several patients, but were always moderate and reversible after withdrawal of the drug. In some patients with a history of peptic ulcer or diabetes mellitus, these conditions were aggravated.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 673314     DOI： 10.1159/000225266

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  7 in total

1.  Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).

Authors:  M Freund; S Wunsch-Zeddies; M Schäfers; J Wysk; I Seidel; W Hiddemann; A R Hanauske; H Link; H J Schmoll; H Poliwoda
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  On the clinical pharmacology of prednimustine.

Authors:  G Plym Forshell; P O Gunnarsson; J Liljekvist
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.

Authors:  H S Jensen; H H Hansen; P Dombernowsky
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Authors:  K E Landys
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

6.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Prednimustine in adult acute myeloid leukaemia.

Authors:  L Brandt; I Könyves
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.